WASHINGTON - U.S. pharmaceutical giant Pfizer Inc. said Monday that its experimental vaccine was more than 90 percent effective in preventing COVID-19 during a late-stage clinical study, raising expectations of a breakthrough in the global fight against the coronavirus pandemic.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
